Search Results

Suggested Reading - My Journey with Leukemia: The Power of Family, Faith, and Humor

My Journey with Leukemia: The Power of Family, Faith, and Humor By Jennifer Venegas
​Published by Outskirts Press, 2018, 175 pages
ISBN: 978-1-4787-7904-9

This book outlines the personal journey of 45 year old Jennifer Venegas who was diagnosed with Ph-positive Acute Lymphoblastic Leukemia.  Jennifer chronicles her daily experience as she undergoes chemotherapy and an allogeneic transplant, then deals with Graft vs Host Disease (GVHD).  From a faith-based perspective, she describes the realities of managing her treatment, her changing roles, and the financial impact of her cancer diagnosis.

My Journey with Leukemia: The Power of Family, Faith, and Humor
Subject
Living with Cancer/Survivorship Side Effects

Suggested Reading - My Blood Brother: A Story About Childhood Leukemia

By Elizabeth Murphy-Melas and Mary Kate Wright (Illustrator)
Health Press NA Inc., 2010, 32 pages
ISBN 9780929173566
Ages 4-10

This touching book explores the dynamics of a family dealing with childhood leukemia. Sam and his older brother, Stefan, learn together that Sam has leukemia. The story shows the emotional turmoil a family endures while coping with a diagnosis of childhood cancer. Although Sam is only seven years old, he learns about how the disease affects his body and the terminology related to his illness. My Blood Brother provides support for the patient, siblings, parents, friends and extended family. The illustrations are done by an award-winning medical illustrator who uses color and technique to provide comfortable, soothing illustrations in contrast with the emotionally charged story line. Parents and young children may benefit from this book.

Targeting non-genetic mechanisms of therapeutic resistance in Acute Myeloid Leukaemia

Drug resistance in AML can develop via a non-genetic process which remains poorly understood. Using our novel cellular barcoding technology that can trace the growth of thousands of cancer cells, our research will identify genes that are switched on or off in AML cells that lead to drug resistance and relapse. This work will reveal the factors underpinning non-genetic drug resistance that may be targeted with new drugs to prevent relapse and ultimately improve quality of life and survival.

Louis J. DeGennaro, Ph.D., to Retire as President and CEO of The Leukemia & Lymphoma Society

FDA Approves First CAR T-Cell Therapy for Chronic Lymphocytic Leukemia

FDA Approves First Targeted Treatment for Newly Diagnosed Leukemia Subtype

Functionalizing novel PHIP variants in ancestry specific Acute Myeloid Leukemia

AML risk stratification established by previous studies do not reflect survival outcomes observed in Black patients. Exome sequencing of 100 Black AML patients revealed the novel variants previously not affiliated with AML, including PHIP. Using multiomic patient sample captures and GEMMs, we will functionalize variants in PHIP and assess if they drive leukemogenesis and/or therapy resistance. The overall goal of this work is to implement inclusive genetic assessment tools for AML diagnosis.

FDA Approves Immunotherapy for Earlier Use in B-cell Acute Lymphoblastic Leukemia

The Leukemia & Lymphoma Society Welcomes Five Members to its Board of Directors

Cancer Crossings: A Brother, His Doctors, and the Quest for a Cure to Childhood Leukemia

Cancer Crossings: A Brother, His Doctors, and the Quest for a Cure to Childhood Leukemia by Tim Wendel
ILR Press, 2018, 256 Pages, Paperback and Kindle
ISBN: 978-1501711039

When Eric Wendel was diagnosed with acute lymphoblastic leukemia in 1966, the survival rate was 10 percent. Today, it is 90 percent. Author Tim Wendel discovered that most of the doctors who cared for his brother at Roswell Park in Buffalo, N.Y., were at the forefront of this medical 'moonshot.' Tim interviewed the doctors and nurses in this effort, including Donald Pinkel, Lucius Sinks, and James Holland. Their medical advancements, as well as his brother's story, are detailed here. 

For more information click here 

Suggested Reading Cancer Crossings
Audience
Adults
Subject
Inspiration

Let's Talk About Childhood Cancer: The Impact of Leukemia in Black Children

Decitabine

Decitabine is FDA approved to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia.

Pegaspargase

Pegaspargase is FDA approved in combination with other chemotherapy medications to treat people who have acute lymphoblastic leukemia (ALL).

Obecabtagene autoleucel

Obecabtagene autoleucel is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Cleaning Tips to Help Keep You and Your Loved Ones Safe

The Leukemia & Lymphoma Society (LLS) is here to help. We’ve put together guidance from the U.S. Centers for Disease Control and Prevention (CDC) and other tips to help caregivers and families keep their homes clean and healthy.

edie and mom

Honoring My Daughter’s Legacy By Continuing Her Fight

Rasburicase

Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.

Calaspargase pegol-mknl

Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. 


 

Alice, myeloma survivor, on a hiking trip, standing in front of mountains

Myeloma Awareness Month: Aiming for more

Moms In Training: Keeping on Track

Staying on track while you train for a walk or run event can be challenging at times. This is especially true for busy moms who barely have enough time to work out, let alone track their fitness progress.

Paying Tribute to a Legacy: Executive Challenge Winners Recognized

This year’s Light The Night Executive Challenge ended with a bittersweet roundup of results. The winner, Stacey Weathers, former long-time executive director of The Leukemia & Lymphoma Society’s (LLS) New Jersey chapter, was tragically killed this past October when a tree fell on her car during a storm. Even though she isn’t here to celebrate with her LLS colleagues and family, her worthy achievement will be recognized as her legacy lives on.  

A Powerful Force

Nelarabine

Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.

Pentostatin

Pentostatin is FDA approved as a single-agent treatment for both untreated and alfa-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia (abnormally low white blood count), thrombocytopenia (reduced platelet count), or disease-related symptoms.

Revumenib

Revumenib is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

SAVE THE DATE AGAIN: GETTING MARRIED AFTER CANCER

My name’s Dustin. December 3, 2016 was the date that I was supposed to get married to KT. It was a Saturday. We had that date set for over a year, but there was no wedding—we canceled it the Tuesday before. KT informed most of our guests with an explanatory text: “So, I have some unfortunate news. We’re going to have to call off the wedding this weekend. Dust got cold feet…and leukemia.”